Postoperative adjuvant immunotherapy for pathological stage II–IVa esophageal squamous cell carcinoma after radical surgery does not improve disease-free recurrence rates
For patients with pathologically confirmed locally advanced ESCC after surgery, postoperative immunotherapy did not confer better disease-free recurrence rates compared to postoperative adjuvant therapy. Nonetheless, with research advancements, the role of immunotherapy in the treatment of ESCC is likely to expand, offering new hope for these patients.
Authors
- Qunqing Chen (ORCID: https://orcid.org/0000-0002-7310-5108)
- Xihao Xie (ORCID: https://orcid.org/0000-0003-4031-7742)
- Bomeng Wu (ORCID: https://orcid.org/0009-0004-0425-4064)
- Ying Chen (ORCID: https://orcid.org/0000-0001-7754-2367)
- Hai Zhang (ORCID: https://orcid.org/0000-0002-9177-3855)
- Wanli Lin (ORCID: https://orcid.org/0009-0001-9680-8973)
- Haiquan He
- Qingyi Feng
Institutions
- Guangdong Medical College (CN)
- Zhujiang Hospital (CN)
- Gaozhou People's Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2024-12-13
- DOI
- https://doi.org/10.3389/fmed.2024.1517001
- Citations
- 1
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.57